Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1000
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

1.0K
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

921
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Audit and Feedback of Targeted Antimicrobials Use at a Tertiary Care Hospital in the United Arab Emirates.

Antibiotics (Basel, Switzerland)·2025
Same author

Sulopenem Etzadroxil/Probenecid.

Hospital pharmacy·2025
Same author

Axatilimab.

Hospital pharmacy·2025
Same author

Respiratory Syncytial Virus Vaccine (mRNA).

Hospital pharmacy·2024
Same author

Resmetirom.

Hospital pharmacy·2024
Same author

Cefepime/Enmetazobactam.

Hospital pharmacy·2024

Related Experiment Video

Updated: Apr 19, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

1.1K

Dapagliflozin.

Dennis J Cada1, Terri L Levien2, Danial E Baker3

  • 1Founder and Contributing Editor, The Formulary , Washington State University , Spokane, Washington.

Hospital Pharmacy
|December 6, 2014
PubMed
Summary

The Formulary Monograph Service provides monthly drug monographs and utilization evaluations for Pharmacy & Therapeutics Committees. This service aids in informed drug selection and safe medication use for healthcare facilities.

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.9K

Related Experiment Videos

Last Updated: Apr 19, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

1.1K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.9K

Area of Science:

  • Pharmaceutical Sciences
  • Clinical Pharmacy

Background:

  • Healthcare facilities require up-to-date information on new and emerging drugs.
  • Pharmacy and Therapeutics (P&T) Committees need comprehensive data for formulary decisions.
  • Drug utilization evaluations (DUE/MUE) are crucial for optimizing medication therapy.

Purpose of the Study:

  • To provide subscribers with detailed monographs on recently approved or late-stage investigational drugs.
  • To offer concise summaries for pharmacy and nursing staff in-services and agenda planning.
  • To deliver comprehensive drug utilization evaluations (DUE/MUE) for key therapeutic agents.

Main Methods:

  • Publication of 5-6 detailed monographs per month covering new and late-phase drugs.
  • Inclusion of 1-page summary monographs for broader staff education.
  • Generation of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) monthly.
  • Monthly drug class reviews integrated into the service.

Main Results:

  • Subscribers receive print and online access to monographs and evaluations.
  • Monographs are customizable to meet specific institutional needs.
  • The July 2014 included monographs on albiglutide, ramucirumab, short ragweed pollen allergen extract, timothy grass pollen allergen extract, and isavuconazole.
  • The July 2014 DUE/MUE focused on albiglutide.

Conclusions:

  • The Formulary Monograph Service offers a valuable, ongoing resource for healthcare professionals.
  • The service supports evidence-based formulary management and medication use.
  • Timely information on new drugs and their utilization is critical for patient care and formulary optimization.